Long-term growth and final adult height outcome in childhood-onset systemic lupus erythematosus

Table 2 Predictors of growth impairment in patients with cSLE

Predictive factors	Univariate		Multivariate
Predictive factors	OR (95% CI)	P value	OR (95% CI)	P value
From time at diagnosis to achieving FAH (N = 106)
Male	5.33 (1.85–15.37)	0.002^a	7.07 (2.11–23.74)	0.002^a
Duration of disease prior to menarche/adult voice appearance (y)	1.27 (1.05–1.53)	0.016^a	1.26 (1.02–1.56)	0.033^a
Cumulative dose of corticosteroids ≥300 mg/kg^b	3.87 (1.07–14.08)	0.040^a	3.91 (0.93–16.37)	0.058
Height impairment at diagnosis^c	3.00 (1.04–8.59)	0.041^a	3.07 (0.92–10.25)	0.068
From time at diagnosis to the late phase of puberty (N = 76)
Male	5.14 (1.59–16.62)	0.006^a	8.87 (2.12–37.17)	0.003^a
Cumulative dose of corticosteroids ≥230 mg/kg^b	4.10 (1.22–13.75)	0.022^a	6.99 (1.63–30.02)	0.009^a

^aP < 0.05 was set as significance; ^bPrednisolone equivalent; ^cHeight impairment: height Z-score less than −1.5; FAH: final adult height

ISSN: 1546-0096